KSF Probes Vertex's $85 Crinetics Bid for Adequacy

Kahn Swick & Foti is investigating whether Vertex Pharmaceuticals' $85-a-share cash bid for Crinetics Pharmaceuticals undervalues the rare-disease drugmaker.

Kahn Swick & Foti opened an investigation into Vertex Pharmaceuticals' proposed $85-a-share cash acquisition of Crinetics Pharmaceuticals, questioning whether the price and the process that produced it adequately compensate shareholders of the Nasdaq-listed biopharmaceutical company.

"We are seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company," Lewis S. Kahn, managing partner at KSF, said.

Under the terms of the proposed transaction, Crinetics shareholders would receive $85.00 in cash for each share they own. KSF, whose partners include former Louisiana Attorney General Charles C. Foti Jr., is examining both the deal's price and the sale process that preceded it. The total enterprise value, the premium to Crinetics' undisturbed share price, and the expected closing timeline have not yet been disclosed.

The investigation adds a layer of legal scrutiny to a deal that would fold Crinetics' pipeline into Vertex, one of the largest drugmakers by market value. If KSF or other shareholders conclude the consideration is inadequate, the firm could press for a higher offer or challenge the transaction in court, potentially delaying the closing and weighing on both CRNX and VRTX shares.

Shareholder litigation is a recurring feature of large pharmaceutical takeovers. When acquirers strike deals at a premium that investors view as too thin, law firms routinely open probes that can extract supplemental disclosures or, in some cases, a bump in price before a shareholder vote. The outcome here will hinge on whether the $85-a-share figure reflects Crinetics' standalone value and the worth of its late-stage programs.

For Crinetics holders, the central question is whether the cash offer captures the full value of the company's pipeline, including its lead candidates and future revenue potential. For Vertex, the risk is that a contested process raises the final price or drags out the timeline, eroding the strategic rationale for the purchase. KSF is inviting shareholders who believe the transaction undervalues the company to contact the firm without obligation or cost.

This article is for informational purposes only and does not constitute investment advice.